Hennion & Walsh Asset Management Inc. Acquires 128,076 Shares of Syndax Pharmaceuticals, Inc. $SNDX

Hennion & Walsh Asset Management Inc. raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 59.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 342,883 shares of the company’s stock after purchasing an additional 128,076 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Syndax Pharmaceuticals were worth $7,495,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Hsbc Holdings PLC lifted its position in shares of Syndax Pharmaceuticals by 3.2% in the 1st quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock worth $556,000 after purchasing an additional 730 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Syndax Pharmaceuticals by 26.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after buying an additional 893 shares in the last quarter. Schroder Investment Management Group lifted its holdings in Syndax Pharmaceuticals by 1.0% during the third quarter. Schroder Investment Management Group now owns 123,404 shares of the company’s stock worth $1,920,000 after buying an additional 1,241 shares during the period. Verition Fund Management LLC lifted its holdings in Syndax Pharmaceuticals by 7.5% during the fourth quarter. Verition Fund Management LLC now owns 18,460 shares of the company’s stock worth $388,000 after buying an additional 1,281 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Syndax Pharmaceuticals by 9.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,562 shares of the company’s stock valued at $374,000 after acquiring an additional 1,455 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SNDX. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Friday, June 12th. Weiss Ratings lowered shares of Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. HC Wainwright decreased their target price on shares of Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Wednesday. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday. Finally, Barclays lifted their price target on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.36.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ SNDX opened at $20.40 on Friday. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.10 and a fifty-two week high of $25.59. The company has a market cap of $1.81 billion, a PE ratio of -8.13 and a beta of 0.40. The company has a debt-to-equity ratio of 38.95, a quick ratio of 5.06 and a current ratio of 6.77. The business has a 50-day simple moving average of $20.43 and a two-hundred day simple moving average of $21.36.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company had revenue of $72.79 million for the quarter, compared to analyst estimates of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The business’s revenue was up 91.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.83) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -1.87 EPS for the current fiscal year.

Trending Headlines about Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $38 price objective, indicating substantial potential upside if Syndax’s pipeline and commercial outlook develop as expected. HC Wainwright Issues Pessimistic Forecast for Syndax Pharmaceuticals
• Neutral Sentiment: The analyst still projects a transition to profitability, forecasting positive EPS of $0.84 in FY2028, $2.28 in FY2029 and $3.16 in FY2030, although those estimates were reduced from previous forecasts.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $1.92 from a loss of $1.16, and lowered its Q3 and Q4 2026 estimates to losses of $0.48 and $0.40 per share, respectively.
• Negative Sentiment: The firm reduced its FY2027 EPS forecast to a loss of $0.41 from a loss of $0.13, suggesting Syndax may remain unprofitable longer than previously expected.
• Negative Sentiment: Longer-term projections were also trimmed: FY2028 EPS fell to $0.84 from $1.17, FY2029 to $2.28 from $2.59, and FY2030 to $3.16 from $3.52. The broad reductions point to more cautious expectations for the company’s earnings trajectory.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 32,375 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total transaction of $784,770.00. Following the sale, the chief executive officer owned 484,843 shares of the company’s stock, valued at approximately $11,752,594.32. The trade was a 6.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Nicholas A.J. Botwood sold 31,235 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $18.14, for a total transaction of $566,602.90. Following the transaction, the chief marketing officer owned 60,885 shares in the company, valued at $1,104,453.90. The trade was a 33.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 105,914 shares of company stock worth $2,120,789. 4.80% of the stock is owned by insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.